Dr. Eduardo Wolffe studies the cutting-edge field of gene editing, which involves making precise changes to DNA. He is particularly interested in how this technology can be used to treat genetic disorders like hemophilia and infections such as HIV/AIDS. Additionally, he has researched the spread of viral infections, specifically how certain mutations in the vaccinia virus can enhance its ability to spread. By understanding these mechanisms, he aims to contribute to the development of more effective vaccines and treatments for viral diseases.
Key findings
Sangamo BioSciences is conducting human clinical trials on gene editing techniques that may provide cures for genetic diseases like hemophilia.
Mutations in the vaccinia virus were found to increase its release and spread by up to 60 times compared to the original virus strain.
The research on virus mutations offers insights that could aid in enhancing vaccine effectiveness and developing better treatment strategies.
Frequently asked questions
Does Dr. Wolffe study gene editing for genetic diseases?
Yes, Dr. Wolffe's research includes gene editing technologies aimed at treating genetic disorders such as hemophilia.
What type of viruses does Dr. Wolffe research?
He studies the vaccinia virus and its mutations, which help in understanding how viruses spread and how to develop better vaccines.
How does Dr. Wolffe's work benefit patients with infectious diseases?
His research on virus mutations and gene editing can lead to improved treatments and vaccines for infectious diseases like HIV/AIDS.
Publications in plain English
Corporate profile: Sangamo BioSciences, Inc.
2016
Regenerative medicine
Wolffe E
Plain English Sangamo BioSciences, Inc. is working on cutting-edge gene editing technology that allows for precise alterations to DNA. They have developed a method using zinc finger proteins to target specific DNA sequences, with plans to use this technology to treat genetic diseases like hemophilia and infections such as HIV/AIDS. Sangamo is currently the only company running human clinical trials with this innovative approach, which holds the potential for cures in conditions that currently have limited treatment options.
Who this helps: Patients with genetic disorders and infectious diseases.
Identification of second-site mutations that enhance release and spread of vaccinia virus.
2002
Journal of virology
Katz E, Wolffe E, Moss B
Plain English This study looked at how certain mutations in the vaccinia virus can help it spread more efficiently. The researchers found five virus clones that were better at spreading due to changes in specific viral proteins, which allowed them to release much more virus into their surroundings—up to 60 times more than the original virus mutant. This is important because understanding how viruses spread can help scientists develop better treatments and vaccines.
Who this helps: This benefits researchers and medical professionals working on vaccines and treatments for viral infections.